COVID Injections Increase Chances of Infection

Data from the United Kingdom

There is a decrease in the efficacy of injections to prevent Sars-Cov-2 infection in all age groups and they show a negative efficacy, i.e. they increase the chance of infection.

Figure 1 Relative risk reduction of Covid-19 infection after vaccination in England. Figure 1 shows that vaccination against Sars-Cov-2 infection not only does not prevent infection, but increases the risk of infection. All age groups demonstrate negative efficacy.

It is not correct to use relative risk reduction, but it is the common metric used during this pandemic to promote injections, we apologize. Also, it makes no difference to the overall story: not only do vaccines not prevent infection, they make you more vulnerable to infection.

Sources: COVID-19 vaccine surveillance report , Week 1 – 6 January 2022

Weekly national Influenza and COVID-19 surveillance report Week 1 report (up to week 52 data) January 2022

It is official, injections against K0 B1T show a negative efficacy. Two studies, one from Canada, one from Denmark, show that 2 doses of K0 B1T injections give a negative result of -38%. Minus 38% means that it increases the chances of infection.
Study shows that receiving 2 doses of COVID-19 vaccine did not protect against Omicron infection at any time, and the VE was -38%. Minus 38% means that it increases the chance of infection.

Conclusion: Two doses of COVID-19 vaccines are unlikely to protect against Omicron infection. While VE against Omicron infection is substantially lower than against Delta infection, a third dose of mRNA vaccine provides some level of protection against Omicron infection in the immediate term. However, the duration of this protection and efficacy against severe disease are uncertain. It is likely that additional tools beyond currently available vaccines, such as public health measures, antivirals, and updated vaccines, will be needed to protect against Omicron infection.

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study


Why mRNA injections are a bad idea

Michael Palmer, MD and Sucharit Bhakdi, MD
Abstract: Pfizer and Moderna’s mRNA-based COVID-19 vaccines have caused injuries and deaths on an unprecedented scale. This brief article explains from basic principles why adverse events should be expected not only after the first injection of such a vaccine, but also after each booster dose. The argument is not limited to SARS-CoV-2 or its spike protein, but generally applies to any non-self antigen introduced in mRNA form. Consequently, not only should COVID mRNA vaccines be stopped, but mRNA vaccines should never be used again, regardless of the infectious agent in question.

  1. Introduction

Readers of the D4CE website will be familiar with the appalling safety record of COVID mRNA vaccines produced by Pfizer and Moderna [1]. A striking feature is that adverse events occur not only after the first injection, but also after each booster dose. In this short article, we will examine the reason for this observation. Other aspects of mRNA vaccine toxicity have been discussed by D4CE before [2,3].

  1. How COVID mRNA vaccines work.

The Pfizer and Moderna mRNA vaccines consist of a synthetic messenger RNA (mRNA) encoding the SARS-CoV-2 “spike protein” normally found on the surface of coronavirus particles. This mRNA is coated with a mixture of synthetic lipids – fat-like molecules – that protect it from degradation during transport within the body and also facilitate its uptake into target cells through endocytosis.

Once the vaccine particle has entered a cell, the lipids are removed and the mRNA is released into the cytosol (the intracellular fluid). The mRNA then binds to ribosomes, the cell’s small protein factories, and directs them to synthesize the actual spike protein molecules. Most of the spike protein molecules will be transported to the cell surface.

Sooner or later, cells expressing this protein, or remnants of such cells, will reach the centers of organization of the immune system in the lymphatic organs. The spike protein will then be recognized by various types of immune cells, including B lymphocytes (B cells), which will begin to produce antibodies against it.

In addition, as with any protein that is synthesized within the cell, a small number of molecules will be fragmented and the fragments will be presented on the cell surface in association with specific carrier proteins (HLA-). The purpose of this mechanism is immune surveillance: as soon as fragments of any protein appear that the immune system does not recognize as “self”, i.e. as belonging to the human body, an immune response will be mounted against any cell that produces it. This response will result in the formation of cytotoxic T-lymphocytes (T-killer cells) that attack and destroy the cells presenting those antigen fragments.

The cytotoxic activity of the T-killer cells will be augmented by several other immune effector mechanisms that are initiated by antibodies. If this combined immune attack occurs to the cells lining the blood vessels, the endothelial cells, the resulting injury may cause blood clotting. Strokes, heart attacks and thrombosis should be expected, and many of these cases have been reported as adverse events following vaccination with the COVID-19 mRNA vaccines from Pfizer and Moderna (as well as the adenovirus-based vaccines produced by AstraZeneca and Johnson & Johnson).

These immunological mechanisms should be expected to operate with any other mRNA-encoded viral antigen. In the case of COVID19 vaccines, there is a second unique pathway that connects spike protein expression with vascular alterations. A centrally important part of the spike protein (the S1 fragment) can be cleaved and released from the cell. The S1 fragment can then bind to blood platelets (thrombocytes) and endothelial cells at remote sites, triggering their activation. This second pathway of triggering vessel damage and blood clots is specific to the SARS-CoV-2 spike protein.

  1. How the immune system deals with natural viruses (or live vaccines).

The reaction of the immune system to the expression of an mRNA vaccine is quite similar to the response of an immunologically inexperienced host to the first infection with a new virus. In this situation, there is nothing to prevent the virus from entering a cell. Once inside the cell, the viral genome will drive the expression of viral proteins, which will again appear on the cell surface, some of them intact and all of them as fragments, as mentioned above. Consequently, cytotoxic T cells and antibody-dependent effector mechanisms will jointly attack the infected cell and kill it. Infected cell death on a sufficiently large scale will result in inflammation and clinical disease.

Now, what happens if we are infected with the same virus again? In this case, we will already have antibodies against it, and these will bind to many of the virus particles and prevent them from entering our body’s cells. On the other hand, virus particles bound to antibodies will be absorbed by phagocytes and will be destroyed. 1

Essentially the same type of immune response is triggered by live virus vaccines, such as, for example, the measles vaccine. The difference is that the strain of virus used for vaccination has been “attenuated” so that it does not cause significant disease even after the first infection.

  1. How the immune system reacts to mRNA vaccines

As noted above, the first injection of an mRNA vaccine will trigger a sequence of events similar to what we see in a viral infection: the mRNA will initiate synthesis of the protein antigen it encodes and the immune system will generate antibodies and cytotoxic T cells directed against that antigen. Together, these will cause cell death.

What happens if we give a booster shot of the same vaccine? Antibodies to the antigen in question will now be present. However, unlike a virus itself, the vaccine particles contain only the mRNA template, but no protein copies of the antigen. Therefore, antibodies will not be able to recognize and bind to the vaccine particles. Consequently, nothing can prevent the mRNA from entering the body’s cells and expressing the antigen, and the immune system from attacking those cells. What’s more, the immune system will already be prepared to attack faster and stronger.

The same will happen not only after the second injection, but after each and every booster injection. Similarly, people who have already had COVID-19 and thus have acquired natural immunity have an increased risk of adverse events even after the first injection of the mRNA vaccine [4,5]. You will be able to draw your own conclusions regarding the wisdom of sentencing people in many jurisdictions, including even those with documented natural immunity, to a seemingly endless series of mRNA booster vaccines against COVID-19.

Why is the first injection of an mRNA vaccine more harmful than that of a conventional live virus vaccine?
The above argument explains why booster injections will be more toxic with mRNA vaccines, but not why even the first injections of COVID-19 mRNA vaccines have caused much more harm than conventional live virus vaccines in the past. There are several aspects to this:

the choice of antigen, i.e., the spike protein, which plays a key role in the pathogenesis of regular COVID-19 disease [6];
the rapid appearance of mRNA vaccines in the bloodstream [3], which will lead to the expression of the spike protein in the endothelial cells of blood vessels, the destruction of these cells by immune attack and blood clotting;
the large amount of mRNA contained in each injection. This amount far exceeds the amount of nucleic acids injected with live attenuated vaccines or absorbed in case of natural infection.
We note that only the first reason mentioned refers specifically to COVID-19 vaccines. The other two are inherent to mRNA vaccine technology as such, and should be expected even with vaccines encoding viral antigens without intrinsic toxicity. At least the final reason given, namely the large administered dose of harmful nucleic acid, also applies to the adenovirus-based vaccines produced by Johnson & Johnson and AstraZeneca. However, with these two vaccines, one would expect the antibody response to the adenoviral vector proteins to mitigate the cell destruction caused by the booster doses.

  1. Conclusion
    We have seen that, for very general and elementary reasons, mRNA technology is inherently more dangerous than live virus vaccines, which are already less safe than inactivated virus vaccines or subunit vaccines (the latter two varieties were not examined in this article). Consequently, COVID-19 mRNA vaccines should not even have been introduced. Their current application should be stopped and any further development of this fundamentally flawed vaccine technology should be halted.

Even if prior to reinfection no antibodies can be detected in the bloodstream because the first infection was a long time ago, we will still have so-called memory B cells, which can be reactivated in a short time and generate a rapid and forceful antibody response; similarly, memory T cells exist and can be activated rapidly. Therefore, although the virus will manage to infect a small number of cells, it will have much less time to spread than the first time: the infection will be cleared quickly and only a negligible number of infected cells will have to be killed. That is why we experience childhood diseases only once: the immune memory is ready to spring into action even after decades. Some viruses can manage to multiply even after “neutralization” and absorption into immune cells. In these cases, the antibodies tend to worsen the disease. This is called antibody-dependent enhancement (ADE) and occurs, for example, with the dengue virus, but also with coronaviruses, including the causative agent of COVID-19 (SARS-CoV-2).

Pfizer’s President admits that his injections are not effective proposes boosters that are harmful:

Goss, J. and Price, M. (2022) Covid-19 Statistics 2022.
Anonymous, (2021) The Dangers of Booster Shots and COVID-19 `Vaccines’: Boosting Blood Clots and Leaky Vessels.
Palmer, M. and Bhakdi, S. (2021) The Pfizer mRNA vaccine: Pharmacokinetics and Toxicity.
Menni, C. et al. (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect. Dis. 21:939-949
Parés-Badell, O. et al. (2021) Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection. Vaccines 9 (preprint)
Marik, P.E. et al. (2021) A scoping review of the pathophysiology of COVID-19. Int. J. Immunopathol. Pharmacol. 35:20587384211048026
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s